Amgen's Q1 2018 earnings call highlighted strong growth in new product sales, particularly outside the US, and solid guidance revisions, including increased revenue and EPS projections.  Management emphasized the positive performance of new products like Repatha, Prolia, and KYPROLIS, along with the upcoming launch of Aimovig which have clear growth potential in the short-term given solid acceptance. The call also indicated continued investment in R&D and a focus on capital repatriation.  These factors suggest a positive short-term impact on the stock price.
[1]
